Risk factors

Ovid Therapeutics updated its financial figures showing cash of $90.4 million and an accumulated deficit of $321.7 million. New risk factors highlight macroeconomic uncertainties, potential FDA disruptions from government shutdowns, and patient population estimation challenges for brain disorders.

The company has added extensive new risks regarding a newly approved digital asset treasury reserve strategy, including custody, volatility, and SEC compliance. Financial disclosures show an accumulated deficit of $100.8 million at December 31, 2025, with cash expected to run out by the second quarter of 2026.

Protalix added risks regarding Brazilian drug purchases and U.S. healthcare laws, and updated risks for Israeli military conflicts and currency exposure.

ProKidney added commercialization risks regarding rilparencel, manufacturing vulnerabilities, and potential NASDAQ delisting.

Increased regulatory focus on commercial real estate and emerging risks from artificial intelligence deployments.

Revenue concentration remains extreme: one OEM supplied 99% of 2025 revenue, despite a long-term AI rack integration agreement.

Macroeconomic updates added references to Iran military actions and April 2025 tariff concerns. Equity plan updated to the 2025 plan with 5250000 reserved shares. Added regulatory oversight risks from banking authorities.

Operating as a blank check company with no revenues or prior history, relying entirely on completing a business combination.

The company faced severe financial deterioration with net losses surging to $19.5 million in 2025. Nasdaq listing compliance risks intensified, prompting a 1-for-15 reverse stock split. Dependency on majority stockholder V-Cube diminished.

ZEVASKYN commercialization now dominates risk disclosure, including market acceptance, treatment-center coordination, manufacturing, supply, regulation, and reimbursement.

The company faces standard blank check risks centered around target acquisition, founder conflicts of interest, and shareholder redemption rights.

Academy Sports & Outdoors added legal risks regarding artificial intelligence and litigation, while expanding disclosures on foreign manufacturing and insurance coverage.